Source: Clinical rheumatology. Unidade: FM
Subjects: VACINAS VIRAIS, COVID-19, DOENÇAS AUTOIMUNES, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PASOTO, Sandra Gofinet et al. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, v. 41, n. 7, p. 2079-2089, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10067-022-06134-x. Acesso em: 01 out. 2024.APA
Pasoto, S. G., Halpern, A. S. R., Guedes, L. K. N., Ribeiro, A. C. M., Yuki, E. N. F., Silva, C. A. A. da, et al. (2022). Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, 41( 7), 2079-2089. doi:10.1007/s10067-022-06134-xNLM
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2024 out. 01 ] Available from: https://doi.org/10.1007/s10067-022-06134-xVancouver
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2024 out. 01 ] Available from: https://doi.org/10.1007/s10067-022-06134-x